{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:07:46Z","timestamp":1778886466798,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["264189"],"award-info":[{"award-number":["264189"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.heliyon.2020.e04368","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T08:42:09Z","timestamp":1594802529000},"page":"e04368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dynamics of HSV-2 infection with a therapeutic vaccine"],"prefix":"10.1016","volume":"6","author":[{"given":"Ezio","family":"Venturino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-8311","authenticated-orcid":false,"given":"Affan","family":"Shoukat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-0227","authenticated-orcid":false,"given":"Seyed M.","family":"Moghadas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2020.e04368_br0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114989","article-title":"Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS ONE"},{"issue":"Supplement_1","key":"10.1016\/j.heliyon.2020.e04368_br0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/343739","article-title":"Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review","volume":"186","author":"Smith","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2020.e04368_br0030","series-title":"Sexually Transmitted Diseases","article-title":"Genital herpes","year":"2007"},{"issue":"6","key":"10.1016\/j.heliyon.2020.e04368_br0040","doi-asserted-by":"crossref","first-page":"958","DOI":"10.7326\/0003-4819-98-6-958","article-title":"Genital herpes simplex virus infections: clinical manifestations, course, and complications","volume":"98","author":"Corey","year":"1983","journal-title":"Ann. Intern. Med."},{"issue":"19","key":"10.1016\/j.heliyon.2020.e04368_br0050","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1056\/NEJMcp023065","article-title":"Genital herpes","volume":"350","author":"Kimberlin","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.heliyon.2020.e04368_br0060","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jama.2011.420","article-title":"Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with hsv-2 infection","volume":"305","author":"Tronstein","year":"2011","journal-title":"JAMA"},{"issue":"suppl_B","key":"10.1016\/j.heliyon.2020.e04368_br0070","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jac\/12.suppl_B.79","article-title":"Treatment of primary first-episode genital herpes simplex virus infections with acyclovir: results of topical, intravenous and oral therapy","volume":"12","author":"Corey","year":"1983","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.heliyon.2020.e04368_br0080","doi-asserted-by":"crossref","first-page":"847","DOI":"10.7326\/0003-4819-121-11-199412010-00004","article-title":"Recurrence rates in genital herpes after symptomatic first-episode infection","volume":"121","author":"Benedetti","year":"1994","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e04368_br0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2020.e04368_br0100","article-title":"Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients","author":"Le Cleach","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.heliyon.2020.e04368_br0110","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1517\/14656566.7.6.665","article-title":"Genital herpes: antiviral therapy for symptom relief and prevention of transmission","volume":"7","author":"Gupta","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"issue":"6","key":"10.1016\/j.heliyon.2020.e04368_br0120","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/sti.75.6.398","article-title":"Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection","volume":"75","author":"Patel","year":"1999","journal-title":"Sex. Transm. Infect."},{"issue":"8911","key":"10.1016\/j.heliyon.2020.e04368_br0130","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(94)92581-X","article-title":"Placebo-controlled trial of vaccination with recombinant glycoprotein d of herpes simplex virus type 2 for immunotherapy of genital herpes","volume":"343","author":"Straus","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2020.e04368_br0140","first-page":"235","article-title":"A double-blind study of the efficacy and safety of the icp10deltapk vaccine against recurrent genital hsv-2 infections","volume":"70","author":"Casanova","year":"2002","journal-title":"Cutis"},{"issue":"3","key":"10.1016\/j.heliyon.2020.e04368_br0150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0264-410X(88)90215-0","article-title":"Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences","volume":"6","author":"Kutinova","year":"1988","journal-title":"Vaccine"},{"issue":"47","key":"10.1016\/j.heliyon.2020.e04368_br0160","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1016\/j.vaccine.2011.09.046","article-title":"Safety and immunogenicity of long hsv-2 peptides complexed with rhhsc70 in hsv-2 seropositive persons","volume":"29","author":"Wald","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.heliyon.2020.e04368_br0170","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.vaccine.2005.08.088","article-title":"A randomized controlled trial of a replication defective (gh deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects","volume":"24","author":"De Bruyn","year":"2006","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.heliyon.2020.e04368_br0180","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.vaccine.2019.05.009","article-title":"Therapeutic hsv-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.heliyon.2020.e04368_br0190","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00007435-200008000-00001","article-title":"A model of the transmission and control of genital herpes","volume":"27","author":"Newton","year":"2000","journal-title":"Sex. Transm. Dis."},{"issue":"10","key":"10.1016\/j.heliyon.2020.e04368_br0200","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1086\/429299","article-title":"Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines","volume":"191","author":"Schwartz","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.heliyon.2020.e04368_br0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4161\/hv.4529","article-title":"Effectiveness and efficiency of imperfect therapeutic hsv-2 vaccines","volume":"3","author":"Schwartz","year":"2007","journal-title":"Hum. Vaccin."},{"issue":"5","key":"10.1016\/j.heliyon.2020.e04368_br0220","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/OLQ.0b013e3181d3d023","article-title":"Population level impact of an imperfect prophylactic hsv-2 vaccine","volume":"37","author":"Alsallaq","year":"2010","journal-title":"Sex. Transm. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2020.e04368_br0230","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/imamat\/hxp030","article-title":"Qualitative dynamics of a vaccination model for hsv-2","volume":"75","author":"Podder","year":"2010","journal-title":"IMA J. Appl. Math."},{"issue":"11","key":"10.1016\/j.heliyon.2020.e04368_br0240","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJM198603133141105","article-title":"Infections with herpes simplex viruses","volume":"314","author":"Corey","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2020.e04368_br0250","series-title":"Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis","author":"Arvin","year":"2007"},{"key":"10.1016\/j.heliyon.2020.e04368_br0260","series-title":"Mathematical Modelling: A Graduate Textbook","author":"Moghadas","year":"2018"},{"key":"10.1016\/j.heliyon.2020.e04368_br0270","series-title":"Modern Simulation and Modeling, vol. 7","author":"Rubinstein","year":"1998"},{"key":"10.1016\/j.heliyon.2020.e04368_br0280","series-title":"Prevalence of herpes simplex virus type 1 and type 2 in persons aged 14-49: United States, 2015-2016","author":"McQuillan","year":"2018"},{"issue":"1","key":"10.1016\/j.heliyon.2020.e04368_br0290","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/sti.2002.003848","article-title":"The potential epidemiological impact of a genital herpes vaccine for women","volume":"80","author":"Garnett","year":"2004","journal-title":"Sex. Transm. Infect."},{"issue":"6","key":"10.1016\/j.heliyon.2020.e04368_br0300","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/infdis\/jix004","article-title":"Therapeutic vaccine for genital herpes simplex virus-2 infection: findings from a randomized trial","volume":"215","author":"Bernstein","year":"2017","journal-title":"J. Infect. Dis."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020312123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020312123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:15:04Z","timestamp":1778883304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844020312123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2405844020312123"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04368","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamics of HSV-2 infection with a therapeutic vaccine","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e04368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e04368"}}